Home › Medicines › Arodex
EN বাং
💊

Arodex

Tablet

🧬 Anastrozole 🏭 Techno Drugs Ltd.
GENERIC NAME
Anastrozole
MANUFACTURER
Techno Drugs Ltd.
UNIT PRICE
Unit Price: ৳ 50.00 (3 x 10: ৳ 1,500.00) Strip Price: ৳ 500.00
Indications
Pharmacology
Dosage & Administration
Interaction
Contraindications
Side Effects
Pregnancy & Lactation
Precautions & Warnings
Storage Conditions

Indications

Arodex is indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer.

Arodex is indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer.

Arodex is indicated for the second-line treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy.

Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to Arodex.

Pharmacology

Arodex is indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer.

Arodex is indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer.

Arodex is indicated for the second-line treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy.

Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to Arodex.

Dosage & Administration

Arodex is indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer.

Arodex is indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer.

Arodex is indicated for the second-line treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy.

Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to Arodex.

Interaction

Arodex is indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer.

Arodex is indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer.

Arodex is indicated for the second-line treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy.

Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to Arodex.

Contraindications

Arodex is indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer.

Arodex is indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer.

Arodex is indicated for the second-line treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy.

Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to Arodex.

Side Effects

Arodex is indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer.

Arodex is indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer.

Arodex is indicated for the second-line treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy.

Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to Arodex.

Pregnancy & Lactation

Arodex is indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer.

Arodex is indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer.

Arodex is indicated for the second-line treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy.

Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to Arodex.

Precautions & Warnings

Arodex is indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer.

Arodex is indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer.

Arodex is indicated for the second-line treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy.

Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to Arodex.

Storage Conditions

Arodex is indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer.

Arodex is indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer.

Arodex is indicated for the second-line treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy.

Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to Arodex.